Bayer’s U.S. chief makes prescription access a test of pharmaceutical innovation

Nelson Ambrogio described an improvement in coverage processing for a menopause medicine and said cash-pay options remain under consideration.

Author
HDM Staff
Save
Share
Nelson Ambrogio speaking with moderator Lydia Ramsey Pflanzer on the Revv Stage
Nelson Ambrogio speaks with moderator Lydia Ramsey Pflanzer on the Revv Stage. Photo credit: HLTH USA 2026

    Bayer’s effort to get a menopause medicine into patients’ hands encountered a problem that better drug discovery could not solve. Roughly two-thirds of its retail prescriptions were initially denied, the company’s U.S. pharmaceuticals president, Nelson Ambrogio, said. After Bayer worked with a partner on benefits verification and access, more than 85% were going through, he said.

    Ambrogio offered that example during a November 17 discussion with Endpoints News deputy editor Lydia Ramsey Pflanzer. Their Revv Stage interview at HLTH USA 2026 examined the forces reshaping pharmaceuticals over the next decade. His account put the operational work after a prescription is written alongside AI-assisted research and U.S. manufacturing investment as a condition for turning a new medicine into meaningful care.

    “A new medicine sitting on a shelf, is not true innovation,” Ambrogio said. The distinction is consequential for health plans, providers and drugmakers that measure success at different points in the process. A regulatory approval, a physician’s treatment decision and a patient’s ability to obtain a medicine each answer a different question, and progress at one point does not establish that the next barrier has disappeared.

    A launch becomes an access problem

    Ambrogio identified Blink as Bayer’s partner in helping patients navigate benefits verification for Lynkuet, its menopause treatment. He presented the change from widespread initial denials to a much higher share of prescriptions going through as an example of improving access after launch. He did not provide the number of prescriptions involved, the observation periods, a breakdown of insurance types or an independently evaluated comparison.

    Those limits matter to what can be concluded from the percentages. An initial denial rate and a later rate of prescriptions proceeding are different operational measures, and the discussion did not establish how many patients started or continued treatment. It also did not identify the respective contributions of benefits verification, changing coverage decisions or other assistance. His figures describe Bayer’s experience, rather than a measured industry-wide effect of an access program.

    The medicine itself is distinct from the process used to obtain it. The FDA approved Lynkuet, or elinzanetant, in October 2025 for moderate-to-severe vasomotor symptoms due to menopause. That established an approved treatment option; Ambrogio’s account addressed the separate work required when a prescription encounters coverage obstacles.

    Ramsey Pflanzer pressed him on whether the experience pointed toward a broader commercial strategy, including direct-to-patient and cash-pay approaches. Ambrogio said different products, therapeutic areas and patients would need different solutions. He treated direct access and cash payment as options Bayer continues to evaluate, rather than announcing a new program or suggesting that one channel would replace all others.

    “Direct to patient and cash pay options certainly offer a new option,” he said. He added that those options merit serious consideration. For patients, however, another way to buy a medicine is useful only to the extent that its price and conditions make it accessible; the session supplied no new cash price or enrollment terms against which to assess that prospect.

    Two different uses for AI

    Ambrogio also separated the research opportunity for artificial intelligence from its role in the commercial organization. In research, he described an AskBio effort that screened a large collection of records against thousands of indications to identify a smaller number worth pursuing. He framed that work as a way to concentrate resources and improve decisions, without presenting it as proof that a drug had reached patients sooner.

    Bayer’s previously stated research ambition is to use AI to increase R&D productivity by 40% by 2030. Ambrogio reiterated the objective as work underway, with early examples of application. A productivity target is not the same as a demonstrated reduction in the full time required to develop, test and secure approval for a medicine, and he did not offer such an end-to-end result.

    On the commercial side, he described tools that help customer-engagement teams decide where to spend time and how to prepare for conversations with healthcare professionals. The examples concerned territory information, prioritization and coaching, rather than an autonomous agent making treatment decisions. Their immediate purpose was to make staff more effective in their existing work.

    His own use of AI began with a less dramatic task: managing email. He said the time it freed could be redirected toward work where he believed he could have more impact. The example helps explain why a drugmaker might adopt AI in administrative and commercial functions before it can show a shorter clinical-development timeline, although the session offered no quantified assessment of those individual productivity gains.

    Investment decisions extend beyond the next policy cycle

    Ramsey Pflanzer asked how U.S. drug-pricing pressure and competition with other countries affected Bayer’s plans. Ambrogio argued that America’s position in biopharmaceutical innovation rests on scientific talent, capital, intellectual-property protection, regulation and a willingness to value new treatments. Those were his policy priorities as an industry executive, not findings establishing which pricing approach produces the best patient outcomes.

    He pointed to Bayer’s Ohio investment as evidence of a longer-term commitment. The company announced the planned $2.2 billion manufacturing site in New Albany on October 2, with a first drug-substance module expected in 2031 and a drug-product module planned for 2034. Those are future facilities, not additional production capacity already operating at the time of his remarks.

    “Our investment decisions are not depending on short term policies,” Ambrogio said. He described the United States as Bayer Pharmaceuticals’ key growth engine and said the commitment covered research and manufacturing as well as commercial operations. The distinction is important because a company can maintain a long-term investment strategy while still facing immediate uncertainty about how individual products will be priced, covered and launched.

    A recent stroke-treatment approval illustrated the next access challenge ahead. Bayer announced FDA approval of Sunharbo, or asundexian, on November 9 for specified patients with recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack, in combination with antiplatelet therapy. Its announcement anticipated initial shipping in mid-to-late November, with availability for ordering following. Approval and distribution were therefore separate milestones.

    Asked what should look different a decade from now, Ambrogio returned to shorter development timelines and fewer delays after prescribing. That made the menopause example more than an aside about a launch: it showed where he believes pharmaceutical companies must prove that innovation reaches patients. The unanswered questions are how consistently those operational improvements can be reproduced, what patients pay, and whether better access ultimately leads to sustained treatment and better health.